GERRESHEIMER should benefit from the launch of Wegovy in Japan. GLP1 products offer a sales opportunity of several hundred million euros!

Novo Nordisk announced today that it plans to launch the weight loss drug Wegovy in Japan on February 22, 2024. This would be the sixth country where the anti-obesity product would be available, despite bottlenecks due to high demand. Gerresheimer is a beneficiary of internationalization, as the Group has all major GLP-1 manufacturers as customers for syringes, pens and autoinjectors.

Gerresheimer believes it is well positioned to secure a significant share of primary packaging and drug delivery systems. The relevant market is worth $1.2-2.4 billion with a market volume of $60 billion for GLP-1 products. Accordingly, Gerresheimer sees the opportunity for sales of several hundred million euros.

The share has undergone a correction in recent weeks. The fall in the share price has made the stock attractive again. The growing internationalization of GLP-1 products is positive for Gerresheimer and should support the share.

Want to keep reading?

You can find the entire story in The Trader Times. Get a 4-week trial subscription now and access the entire archive!

array (
  'ID' => '746',
  'post_date' => '2023-09-15 17:23:38',
  'post_date_gmt' => '2023-09-15 15:23:38',
  'post_content' => '',
  'post_title' => 'Top Stories from The Trader Times',
  'post_type' => 'page',
  'post_excerpt' => '/top-stories/',
  'post_status' => 'publish',
  'post_name' => 'en-top-stories',
  'post_modified' => '2023-11-22 15:39:06',
  'post_modified_gmt' => '2023-11-22 14:39:06',
  'post_parent' => '29',
  'commercial_a' => '',
  'commercial_a_label_subscribe' => 'Subscribe Now',
  'commercial_a_text' => 'You can find the entire story in The Trader Times.',
  'commercial_a_text_download' => 'Read the full issue now',
  'commercial_a_text_subscribe' => 'Get a 4-week trial subscription now and access the entire archive!',
  'commercial_a_title' => 'Want to keep reading?',
  'download_label' => 'Read the issue',
  'order_alert' => 'Tip: Try our newspaper today with a 4-week trial subscription!',
  'order_label' => 'Get a trial subscription',
  'seo_description' => '',
  'seo_image' => '',
  'seo_title' => '',
  'link' => '/top-stories/',
)
array (
  'ID' => '1841',
  'post_author' => 
  array (
    'ID' => '2',
    'user_url' => '',
    'display_name' => 'Tabea Kletterer',
    'user_registered' => '2023-09-12 13:11:15',
    'nickname' => 'TabeaKletterer',
    'first_name' => 'Tabea',
    'last_name' => 'Kletterer',
    'description' => '',
    'name' => 'Tabea Kletterer',
    'name_short' => 'T. Kletterer',
  ),
  'post_date' => '2023-11-27 17:57:38',
  'post_date_gmt' => '2023-11-27 16:57:38',
  'post_content' => '

Novo Nordisk announced today that it plans to launch the weight loss drug Wegovy in Japan on February 22, 2024. This would be the sixth country where the anti-obesity product would be available, despite bottlenecks due to high demand. Gerresheimer is a beneficiary of internationalization, as the Group has all major GLP-1 manufacturers as customers for syringes, pens and autoinjectors.

Gerresheimer believes it is well positioned to secure a significant share of primary packaging and drug delivery systems. The relevant market is worth $1.2-2.4 billion with a market volume of $60 billion for GLP-1 products. Accordingly, Gerresheimer sees the opportunity for sales of several hundred million euros.

The share has undergone a correction in recent weeks. The fall in the share price has made the stock attractive again. The growing internationalization of GLP-1 products is positive for Gerresheimer and should support the share.

', 'post_title' => 'GERRESHEIMER should benefit from the launch of Wegovy in Japan. GLP1 products offer a sales opportunity of several hundred million euros!', 'post_excerpt' => '', 'post_status' => 'publish', 'comment_status' => 'open', 'ping_status' => 'open', 'post_password' => '', 'post_name' => 'gerresheimer-should-benefit-from-the-launch-of-wegovy-in-japan-glp1-products-offer-a-sales-opportunity-of-several-hundred-million-euros', 'to_ping' => '', 'pinged' => '', 'post_modified' => '2023-11-28 15:56:07', 'post_modified_gmt' => '2023-11-28 14:56:07', 'post_content_filtered' => '', 'post_parent' => '0', 'guid' => 'https://tradertimes.com/wordpress/?p=1841', 'menu_order' => '0', 'post_type' => 'post', 'post_mime_type' => '', 'comment_count' => '0', '_encloseme' => '1', '_pingme' => '1', '_thumbnail_id' => '1855', 'magazine' => array ( 'ID' => '1834', 'post_author' => '2', 'post_date' => '2023-11-27 17:51:46', 'post_date_gmt' => '2023-11-27 16:51:46', 'post_content' => '', 'post_title' => 'Trader Times #51 dated November 25, 2023', 'post_excerpt' => '', 'post_status' => 'publish', 'post_name' => 'trader-times-51-dated-november-25-2023', 'post_modified' => '2023-11-27 17:51:46', 'post_modified_gmt' => '2023-11-27 16:51:46', 'post_parent' => '0', 'post_type' => 'tradertimes', 'description' => '

The Trader Times reports daily at 8 AM (EDT) on exciting stock news and new buying opportunities! In our articles, we combine neutral coverage of stocks with the clear opinions of our editors. With 8 systematically conducted screening routines, we ensure that no top story escapes us!

', 'issue' => '51', 'newsletter' => '

Dear Traders

The Trader Times reports daily at 8 AM (EDT) on exciting stock news and new buying opportunities! In our articles, we combine neutral coverage of stocks with the clear opinions of our editors. With 8 systematically conducted screening routines, we ensure that no top story escapes us!

You can find the archive here: https://tradertimes.com/archive/

Best regards,
Simon Betschinger

', 'pdf' => array ( 'ID' => '1835', 'post_title' => '20231124_Trader-Zeitung_146_EN', 'post_content' => '', 'post_date' => '2023-11-27 17:51:21', 'post_type' => 'attachment', 'post_mime_type' => 'application/pdf', 'post_parent' => '1834', 'src' => 'https://tradertimes.com/files/2023/11/20231124_Trader-Zeitung_146_EN.pdf', 'thumbnail' => 'https://tradertimes.com/files/2023/11/20231124_Trader-Zeitung_146_EN-pdf-image.jpg', ), 'title' => 'Exciting Stocks', ), 'seo_description' => '', 'seo_image' => '', 'seo_title' => '', 'teaser' => '', 'category' => array ( 9 => array ( 'term_id' => '9', 'term_taxonomy_id' => '9', 'name' => 'Top Stories', 'slug' => 'top-stories', 'description' => '', 'parent' => '0', 'lang_term_taxonomy_id' => '8', 'lang_term_id' => '8', 'lang_name' => 'English', 'lang_slug' => 'en', 'translations' => array ( 'de' => 1, 'en' => 9, 'es' => 13, 'fr' => 17, 'it' => 21, ), 'seo_title' => '', 'seo_description' => '', 'seo_image' => '', 'sub_ids' => array ( 0 => 9, ), 'link' => '/top-stories/', ), ), 'link' => '/top-stories/gerresheimer-should-benefit-from-the-launch-of-wegovy-in-japan-glp1-products-offer-a-sales-opportunity-of-several-hundred-million-euros-1841.html', 'image' => array ( 'ID' => '1855', 'post_author' => '2', 'post_date' => '2023-11-28 15:55:46', 'post_date_gmt' => '2023-11-28 14:55:46', 'post_content' => '', 'post_title' => 'siegen, North Rhine Westphalia, germany - 10 11 2023: a injection concept of wegovy weight loss medication', 'post_excerpt' => 'siegen, North Rhine Westphalia , germany - 10 11 2023: a injection concept of wegovy weight loss medication', 'post_status' => 'inherit', 'post_name' => 'siegen-north-rhine-westphalia-germany-10-11-2023-a-injection-concept-of-wegovy-weight-loss-medication', 'post_modified' => '2023-11-28 15:56:05', 'post_modified_gmt' => '2023-11-28 14:56:05', 'post_parent' => '1841', 'post_type' => 'attachment', '_wp_attached_file' => '2023/11/AdobeStock_676580837_Editorial_Use_Only-scaled.jpeg', '_wp_attachment_metadata' => 'a:7:{s:5:"width";i:2560;s:6:"height";i:1707;s:4:"file";s:59:"2023/11/AdobeStock_676580837_Editorial_Use_Only-scaled.jpeg";s:8:"filesize";i:396401;s:5:"sizes";a:6:{s:9:"thumbnail";a:5:{s:4:"file";s:52:"AdobeStock_676580837_Editorial_Use_Only-150x150.jpeg";s:5:"width";i:150;s:6:"height";i:150;s:9:"mime-type";s:10:"image/jpeg";s:8:"filesize";i:15511;}s:9:"1536x1536";a:5:{s:4:"file";s:54:"AdobeStock_676580837_Editorial_Use_Only-1536x1024.jpeg";s:5:"width";i:1536;s:6:"height";i:1024;s:9:"mime-type";s:10:"image/jpeg";s:8:"filesize";i:192751;}s:9:"2048x2048";a:5:{s:4:"file";s:54:"AdobeStock_676580837_Editorial_Use_Only-2048x1365.jpeg";s:5:"width";i:2048;s:6:"height";i:1365;s:9:"mime-type";s:10:"image/jpeg";s:8:"filesize";i:287617;}s:6:"teaser";a:5:{s:4:"file";s:52:"AdobeStock_676580837_Editorial_Use_Only-632x280.jpeg";s:5:"width";i:632;s:6:"height";i:280;s:9:"mime-type";s:10:"image/jpeg";s:8:"filesize";i:44579;}s:7:"content";a:5:{s:4:"file";s:54:"AdobeStock_676580837_Editorial_Use_Only-1296x3648.jpeg";s:5:"width";i:1296;s:6:"height";i:3648;s:9:"mime-type";s:10:"image/jpeg";s:8:"filesize";i:418934;}s:2:"fb";a:5:{s:4:"file";s:53:"AdobeStock_676580837_Editorial_Use_Only-1200x628.jpeg";s:5:"width";i:1200;s:6:"height";i:628;s:9:"mime-type";s:10:"image/jpeg";s:8:"filesize";i:116370;}}s:10:"image_meta";a:12:{s:8:"aperture";s:1:"0";s:6:"credit";s:33:"Tobias Arhelger - stock.adobe.com";s:6:"camera";s:0:"";s:7:"caption";s:107:"siegen, North Rhine Westphalia , germany - 10 11 2023: a injection concept of wegovy weight loss medication";s:17:"created_timestamp";s:1:"0";s:9:"copyright";s:0:"";s:12:"focal_length";s:1:"0";s:3:"iso";s:1:"0";s:13:"shutter_speed";s:1:"0";s:5:"title";s:107:"siegen, North Rhine Westphalia , germany - 10 11 2023: a injection concept of wegovy weight loss medication";s:11:"orientation";s:1:"1";s:8:"keywords";a:68:{i:0;s:6:"wegovy";i:1;s:16:"wegovy injection";i:2;s:11:"wegovy logo";i:3;s:11:"wegovy sign";i:4;s:4:"care";i:5;s:6:"clinic";i:6;s:7:"closeup";i:7;s:9:"diagnosis";i:8;s:6:"doctor";i:9;s:5:"glove";i:10;s:5:"hands";i:11;s:6:"health";i:12;s:10:"healthcare";i:13;s:7:"illness";i:14;s:6:"inject";i:15;s:9:"injection";i:16;s:7:"medical";i:17;s:8:"medicine";i:18;s:6:"needle";i:19;s:7:"sterile";i:20;s:7:"syringe";i:21;s:11:"therapeutic";i:22;s:7:"therapy";i:23;s:9:"treatment";i:24;s:11:"vaccination";i:25;s:4:"2023";i:26;s:6:"siegen";i:27;s:14:"10 of november";i:28;s:12:"novo nordisk";i:29;s:7:"germany";i:30;s:17:"danish medication";i:31;s:14:"danish company";i:32;s:11:"lose weight";i:33;s:21:"weight loss injection";i:34;s:6:"wegovy";i:35;s:16:"wegovy injection";i:36;s:11:"wegovy logo";i:37;s:11:"wegovy sign";i:38;s:4:"care";i:39;s:6:"clinic";i:40;s:7:"closeup";i:41;s:9:"diagnosis";i:42;s:6:"doctor";i:43;s:5:"glove";i:44;s:5:"hands";i:45;s:6:"health";i:46;s:10:"healthcare";i:47;s:7:"illness";i:48;s:6:"inject";i:49;s:9:"injection";i:50;s:7:"medical";i:51;s:8:"medicine";i:52;s:6:"needle";i:53;s:7:"sterile";i:54;s:7:"syringe";i:55;s:11:"therapeutic";i:56;s:7:"therapy";i:57;s:9:"treatment";i:58;s:11:"vaccination";i:59;s:4:"2023";i:60;s:6:"siegen";i:61;s:14:"10 of november";i:62;s:12:"novo nordisk";i:63;s:7:"germany";i:64;s:17:"danish medication";i:65;s:14:"danish company";i:66;s:11:"lose weight";i:67;s:21:"weight loss injection";}}s:14:"original_image";s:44:"AdobeStock_676580837_Editorial_Use_Only.jpeg";}', 'src' => 'https://tradertimes.com/files/2023/11/AdobeStock_676580837_Editorial_Use_Only-scaled.jpeg', 'meta' => array ( 'width' => 2560, 'height' => 1707, 'file' => '2023/11/AdobeStock_676580837_Editorial_Use_Only-scaled.jpeg', 'filesize' => 396401, 'sizes' => array ( 'thumbnail' => array ( 'file' => 'AdobeStock_676580837_Editorial_Use_Only-150x150.jpeg', 'width' => 150, 'height' => 150, 'mime-type' => 'image/jpeg', 'filesize' => 15511, ), '1536x1536' => array ( 'file' => 'AdobeStock_676580837_Editorial_Use_Only-1536x1024.jpeg', 'width' => 1536, 'height' => 1024, 'mime-type' => 'image/jpeg', 'filesize' => 192751, ), '2048x2048' => array ( 'file' => 'AdobeStock_676580837_Editorial_Use_Only-2048x1365.jpeg', 'width' => 2048, 'height' => 1365, 'mime-type' => 'image/jpeg', 'filesize' => 287617, ), 'teaser' => array ( 'file' => 'AdobeStock_676580837_Editorial_Use_Only-632x280.jpeg', 'width' => 632, 'height' => 280, 'mime-type' => 'image/jpeg', 'filesize' => 44579, ), 'content' => array ( 'file' => 'AdobeStock_676580837_Editorial_Use_Only-1296x3648.jpeg', 'width' => 1296, 'height' => 3648, 'mime-type' => 'image/jpeg', 'filesize' => 418934, ), 'fb' => array ( 'file' => 'AdobeStock_676580837_Editorial_Use_Only-1200x628.jpeg', 'width' => 1200, 'height' => 628, 'mime-type' => 'image/jpeg', 'filesize' => 116370, ), ), 'image_meta' => array ( 'aperture' => '0', 'credit' => 'Tobias Arhelger - stock.adobe.com', 'camera' => '', 'caption' => 'siegen, North Rhine Westphalia , germany - 10 11 2023: a injection concept of wegovy weight loss medication', 'created_timestamp' => '0', 'copyright' => '', 'focal_length' => '0', 'iso' => '0', 'shutter_speed' => '0', 'title' => 'siegen, North Rhine Westphalia , germany - 10 11 2023: a injection concept of wegovy weight loss medication', 'orientation' => '1', 'keywords' => array ( 0 => 'wegovy', 1 => 'wegovy injection', 2 => 'wegovy logo', 3 => 'wegovy sign', 4 => 'care', 5 => 'clinic', 6 => 'closeup', 7 => 'diagnosis', 8 => 'doctor', 9 => 'glove', 10 => 'hands', 11 => 'health', 12 => 'healthcare', 13 => 'illness', 14 => 'inject', 15 => 'injection', 16 => 'medical', 17 => 'medicine', 18 => 'needle', 19 => 'sterile', 20 => 'syringe', 21 => 'therapeutic', 22 => 'therapy', 23 => 'treatment', 24 => 'vaccination', 25 => '2023', 26 => 'siegen', 27 => '10 of november', 28 => 'novo nordisk', 29 => 'germany', 30 => 'danish medication', 31 => 'danish company', 32 => 'lose weight', 33 => 'weight loss injection', 34 => 'wegovy', 35 => 'wegovy injection', 36 => 'wegovy logo', 37 => 'wegovy sign', 38 => 'care', 39 => 'clinic', 40 => 'closeup', 41 => 'diagnosis', 42 => 'doctor', 43 => 'glove', 44 => 'hands', 45 => 'health', 46 => 'healthcare', 47 => 'illness', 48 => 'inject', 49 => 'injection', 50 => 'medical', 51 => 'medicine', 52 => 'needle', 53 => 'sterile', 54 => 'syringe', 55 => 'therapeutic', 56 => 'therapy', 57 => 'treatment', 58 => 'vaccination', 59 => '2023', 60 => 'siegen', 61 => '10 of november', 62 => 'novo nordisk', 63 => 'germany', 64 => 'danish medication', 65 => 'danish company', 66 => 'lose weight', 67 => 'weight loss injection', ), ), 'original_image' => 'AdobeStock_676580837_Editorial_Use_Only.jpeg', ), ), 'translations' => array ( 'de' => array ( 'post_title' => 'GERRESHEIMER sollte von der Einführung von Wegovy in Japan profitieren. GLP1-Produkte bieten mehrere hundert Millionen-Euro-Umsatzchance!', 'post_name' => '', 'ID' => '1840', 'post_type' => 'post', 'link' => '/de/top-storys/-1840.html', ), 'en' => array ( 'post_title' => 'GERRESHEIMER should benefit from the launch of Wegovy in Japan. GLP1 products offer a sales opportunity of several hundred million euros!', 'post_name' => 'gerresheimer-should-benefit-from-the-launch-of-wegovy-in-japan-glp1-products-offer-a-sales-opportunity-of-several-hundred-million-euros', 'ID' => '1841', 'post_type' => 'post', 'link' => '/top-stories/gerresheimer-should-benefit-from-the-launch-of-wegovy-in-japan-glp1-products-offer-a-sales-opportunity-of-several-hundred-million-euros-1841.html', ), 'es' => array ( 'post_title' => 'GERRESHEIMER debería beneficiarse del lanzamiento de Wegovy en Japón. Los productos GLP1 ofrecen una oportunidad de venta de varios cientos de millones de euros.', 'post_name' => 'gerresheimer-debera-beneficiarse-del-lanzamiento-de-wegovy-en-japn-los-productos-glp1-ofrecen-una-oportunidad-de-venta-de-varios-cientos-de-millones-de-euros', 'ID' => '1842', 'post_type' => 'post', 'link' => '/es/noticias-principales/gerresheimer-debera-beneficiarse-del-lanzamiento-de-wegovy-en-japn-los-productos-glp1-ofrecen-una-oportunidad-de-venta-de-varios-cientos-de-millones-de-euros-1842.html', ), 'fr' => array ( 'post_title' => 'GERRESHEIMER devrait profiter du lancement de Wegovy au Japon. Les produits GLP1 représentent une opportunité de chiffre d\'affaires de plusieurs centaines de millions d\'euros !', 'post_name' => 'gerresheimer-devrait-profiter-du-lancement-de-wegovy-au-japon-les-produits-glp1-reprsentent-une-opportunit-de-chiffre-daffaires-de-plusieurs-centaines-de-millions-deuros', 'ID' => '1843', 'post_type' => 'post', 'link' => '/fr/actualites-principales/gerresheimer-devrait-profiter-du-lancement-de-wegovy-au-japon-les-produits-glp1-reprsentent-une-opportunit-de-chiffre-daffaires-de-plusieurs-centaines-de-millions-deuros-1843.html', ), 'it' => array ( 'post_title' => 'GERRESHEIMER dovrebbe trarre vantaggio dal lancio di Wegovy in Giappone. I prodotti GLP1 offrono un\'opportunità di vendita di diverse centinaia di milioni di euro!', 'post_name' => 'gerresheimer-dovrebbe-trarre-vantaggio-dal-lancio-di-wegovy-in-giappone-i-prodotti-glp1-offrono-unopportunit-di-vendita-di-diverse-centinaia-di-milioni-di-euro', 'ID' => '1844', 'post_type' => 'post', 'link' => '/it/notizie-principali/gerresheimer-dovrebbe-trarre-vantaggio-dal-lancio-di-wegovy-in-giappone-i-prodotti-glp1-offrono-unopportunit-di-vendita-di-diverse-centinaia-di-milioni-di-euro-1844.html', ), ), )